McCallum Lucas, Faunce Thomas
J Law Med. 2015 Dec;23(2):322-9.
The Australian High Court's recent landmark decision in D'Arcy v Myriad Genetics Inc overturned the decision by the Federal Court in Cancer Voices Australia v Myriad Genetics Inc regarding patenting of genetic material. The Federal Court had found that isolated DNA and RNA can constitute a patentable invention under s 18(1)(a) of the Patents Act 1990 (Cth). The decision by the High Court unanimously reversed this and declared it was appropriate to look to the policy implications at the heart of the legal question: are genes a category of things that can be patented? This column critically examines the implications of the High Court decision for both research and public health in Australia.
澳大利亚高等法院近期在达西诉麦利亚德基因公司案中做出的具有里程碑意义的裁决,推翻了联邦法院在澳大利亚癌症之声组织诉麦利亚德基因公司案中关于基因材料专利问题的裁决。联邦法院曾认定,分离出的DNA和RNA可根据1990年《澳大利亚专利法》(联邦)第18(1)(a)条构成可获专利的发明。高等法院的裁决一致推翻了这一认定,并宣称应考量法律问题核心的政策影响:基因是否属于可获专利的事物类别?本专栏将批判性地审视高等法院这一裁决对澳大利亚研究和公共卫生的影响。